title: Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
abstract: OBJECTIVE
  The aims of this study were (1) to explore physicians' self-reported treatment of patients with dyslipidemia and (2) to identify intercountry differences and associations between physicians' characteristics and treatment patterns.
  
  
  METHODS
  A cross-sectional survey was performed in primary health care in 9 Central and Eastern European countries. An anonymous questionnaire, which included questions devoted to dyslipidemia treatment, was distributed.
  
  
  RESULTS
  A total of 3000 physicians were randomly chosen and 867 responded. The mean percentage of physicians in all countries who reported regular use of statins in primary prevention of cardiovascular diseases (CVD) was 86.4 (range between 91.0% of Polish physicians and 75.7% of Czech physicians; P < .01). In secondary prevention, the mean percentage was only a little higher, 89.9. The use of fibrates for primary prevention was reported by 40.3% of the respondents from Bulgaria and by 2% of the respondents from Estonia (P < .01). Also, significant differences between countries were found in the use of fibrates and combination therapy in secondary prevention. Atorvastatin and simvastatin were the most prescribed drugs in everyday practice (the mean percentage of physicians in all countries was 72.5% and 68.0%, respectively). More than three-fourth of the respondents reported prescribing lifelong treatment with statins. Inconsistent associations were found between the characteristics of physicians and their treatment patterns.
  
  
  CONCLUSIONS
  There are significant variations in the use of lipid-lowering drugs in Central and Eastern European countries; however, statin monotherapy predominates. Some physicians' decisions are made without supporting evidence from clinical trials. There is still scope to improve preventive care of CVD.
authors.affiliation: Department of Family Medicine, Jagiellonian University Medical College, Krakow, Poland. mmtomasi@cyf-kr.edu.pl
authors.forename: Tomasz
authors.initials: T
authors.lastname: Tomasik
authors.forename: Adam
authors.initials: A
authors.lastname: Windak
authors.forename: Bohumil
authors.initials: B
authors.lastname: Seifert
authors.forename: Janko
authors.initials: J
authors.lastname: Kersnik
authors.forename: Violetta
authors.initials: V
authors.lastname: Kijowska
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Dubas
mesh_terms: D000328:Adult; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003430:Cross-Sectional Studies; D011307:Drug Prescriptions; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000188:drug therapy* / Q000503:physiopathology; D005060:Europe / Q000453:epidemiology; D005260:Female; D019538:Health Care Surveys; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D058007:Physicians, Primary Care; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011758:Pyrroles / Q000627:therapeutic use; D012306:Risk; D063127:Secondary Health Care; D057566:Self Report; D019821:Simvastatin / Q000627:therapeutic use
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin